Baxter
Revaclear
DIALYZER

Revaclear

DESIGNED FOR:
HFHD (High flux)

OTHER APPLICABLE THERAPIES:
CONVECTIVE (HDF)

MEMBRANE:
PORACTON (PAES/PVP, BPA-free)

OPTIMIZING HIGH FLUX PERFORMANCE

The **Revaclear** dialyzer series is a range of high efficiency high-flux dialyzers designed to enhance safety and biocompatibility for your patients, while optimizing clearance with a smaller surface area.[1]

OPTIMIZING PERFORMANCE FOR ALL YOUR PATIENTS[2]

The **Revaclear** dialyzers are designed to optimize the performance of high-flux treatments.

- The **Poracton** membrane provides effective permeability with minimal resistance to diffusion[3,4,5]
- Three surface area options are available to meet individual patient needs
- Study in HD showed **Revaclear** 400 to remove small solutes and β_2-microglobulin to a similar extent as a 22% larger surface area dialyzer[2]

WITH SAFETY AND BIOCOMPATIBILITY IN MIND

The relative compact surface area of the **Revaclear** dialyzers may help manage some patient risks.

- Reduces exposure of blood, potentially reducing clotting and micro inflammation[6]
- Produces less biohazardous waste and reduces saline need, compared to dialyzers of the same performance[7,8]

Revaclear Specifications

MATERIALS	REVACLEAR 300	REVACLEAR 400	REVACLEAR 500
Membrane		**Poracton** Polyarylethersulfone and Polyvinylpyrrolidone blend BPA-free	
Potting		Polyurethane (PUR)	
Housing		Polycarbonate (PC)	
Gaskets		Silicone rubber (SIR)	
Protection caps		Polypropylene (PP)	
Sterilization		Steam (inside-out)	
Sterile barrier		Tyvek	

SPECIFICATIONS			
UF-Coefficient (mL/(h*mmHg))*	48	54	65
KoA urea*	1186	1439	1578
Blood Compartment volume (mL)	74	93	106
Minimum recommended priming volume (mL)		300	
Maximum TMP (mmHg)		600	
Recommended Q_B (mL/min)	200-500	200-600	250-600
Storage conditions		<30°C (or <86°F)	
Units per box		24	
Gross/net weight (g)	215/160	225/170	250/190

MEMBRANE			
Effective Membrane Area (m²)	1.4	1.8	2.1
Fiber inner diameter (µm)		190	
Fiber wall thickness (µm)		35	

SIEVING COEFFICIENTS*	
Vitamin B12 (1,4 kDa)	1.0
Inulin (5,2 kDa)	1.0
$ß_2$-microglobulin (11,8 kDa)	0.95
Myoglobin (17 kDa)	0.68
Albumin (66,4 kDa)	0.0027

* According to EN 1283/ISO 8637:
– UF-Coefficient: measured with bovine blood, Hct 32%, Pct 60g/L, 37°C
– KoA urea: calculated at Q_B=300 mL/min, Q_D=500mL/min, UF=0 mL/min
– Sieving coefficients: measured with human plasma, Q_B=300 mL/min, UF=60 mL/min
– Clearances In-Vitro: measured at UF=0 mL/min, ±10%

CLEARANCES IN VITRO (mL/min)*	REVACLEAR 300	REVACLEAR 400	REVACLEAR 500
Urea (60 Da) (Q_B-Q_D, mL/min)			
200-250**/500	196	198	244
300/500	272	281	284
400/500	323	338	345
400/800	355	369	375
500/800	408	430	439
Creatinine (113 Da)			
200-250**/500	191	195	238
300/500	256	267	272
400/500	298	315	323
400/800	330	348	355
500/800	373	398	409
Phosphates (142 Da)			
200-250**/500	185	191	230
300/500	242	255	261
400/500	278	297	306
400/800	309	330	338
500/800	345	373	384
Vitamin B12 (1.4 kDa)			
200-250**/500	146	158	183
300/500	174	191	200
400/500	191	213	223
400/800	212	236	247
500/800	228	256	269

** REVACLEAR 500

1. Baxter. *REVACLEAR White Paper*. USMP/MG3/140052, May 2013.
2. Mauric A, et al. *Poster SP401*, presented at 50th ERA-EDTA congress. Istanbul (Turkey), 2013.
3. Ronco C, et al. *Evolution of synthetic membranes for blood purification: the case of the Polyflux family*. Nephrol Dial Transplant 2003;18(Suppl 7):vii10-20.
4. Ward R, et al. *Abstract SA-PO510*, presented at the 40th ASN congress. San Francisco (USA), 2007.
5. Bhimani JP, et al. *Effect of increasing dialysate flow rate on diffusive mass transfer of urea, phosphate and beta2-microglobulin during clinical haemodialysis*. Nephrol Dial Transplant 2010; 25:3990-3995.
6. Yao Q, et al. *Inflammation as a cause of malnutrition, atherosclerotic cardiovascular disease, and poor outcome in hemodialysis patients*. Hemodial Int 2004; 8:118-129.
7. Baxter. Data on file. *Biohazardous waste cost calculation*, 2015.
8. Baxter. *REVACLEAR dialyzer priming guide*. 306150152_C, 2009.

The products meet the applicable provisions of Annex I (Essential Requirements) and Annex II (Full quality assurance system of the Council Directive 93/42/EEC of 14 June 1993, amended by Directive 2007/47/EC)

For safe and proper use of the device, please refer to the Instructions for Use

CE 0086

MANUFACTURER
Gambro Dialysatoren GmbH
Holger-Crafoord-Strasse 26
72379 Hechingen
Germany

Baxter Healthcare Corporation
One Baxter Parkway
Deerfield, IL 60015
USA
1-800-422-9837

GLBL/MG3/18-0020a –January 2019